Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C

Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C

Scientific relevance. Direct-acting antivirals have significantly improved the effectiveness of treatment for hepatitis C. However, Russia and the Eurasian Economic Union lack recommendations for the clinical development of medicinal products from this pharmacotherapeutic group.Aim. The study aimed...

Full description

Bibliographic Details
Main Authors:	A. I. Gubenko, D. V. Goryachev, A. I. Muravieva, G. V. Shukshina
Format:	Article
Language:	Russian
Published:	NEICON ISP LLC 2023-12-01
Series:	Ведомости Научного центра экспертизы средств медицинского применения
Subjects:	clinical trials direct-acting antivirals chronic viral hepatitis c hepatitis c virus eaeu
Online Access:	https://www.vedomostincesmp.ru/jour/article/view/499

Similar Items

Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
by: Erica Nicola Lynch, et al.
Published: (2023-03-01)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
by: Vicente Soriano, et al.
Published: (2022-01-01)

Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients
by: Hsu-Heng Yen, et al.
Published: (2021-03-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

The Outcomes of Direct-acting Antiviral Treatment in 177 Patients with Hepatitis C Virus: A Single-center Experience
by: Ayşin KILINÇ TOKER, et al.
Published: (2023-12-01)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
by: Asma Ahmed, et al.
Published: (2015-12-01)

Antiviral therapy in chronic hepatitis C virus infection
by: Irina Russu
Published: (2019-09-01)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
by: Soon Young Ko, et al.
Published: (2018-12-01)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
by: Chung-Feng Huang, et al.
Published: (2020-07-01)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
by: Paweł Pabjan, et al.
Published: (2022-01-01)

Chronic Hepatitis C Treatment with New Antiviral Agents
by: Özlem KANDEMİR
Published: (2018-12-01)

Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
by: Mohamed M Sakr, et al.
Published: (2019-01-01)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
by: Byung Soo Kwan, et al.
Published: (2021-03-01)

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis
by: Christiana Graf, et al.
Published: (2020-08-01)

Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct‐acting antivirals
by: Satoshi Takakusagi, et al.
Published: (2022-04-01)

Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature
by: Mohit Bhatia, et al.
Published: (2020-01-01)

Direct-Acting Antiviral Drugs Reduce Fibromyalgia Symptoms in Patients with Chronic Hepatitis C
by: Kuo-Tung Tang, et al.
Published: (2022-09-01)

Detection of drug resistance mutations of hepatitis C virus in patients with failure of the treatment with direct acting antivirals
by: D. E. Valutite, et al.
Published: (2021-03-01)

Assessment of serum Resistin in detecting Insulin Resistance and their impact on response to direct acting antiviral in chronic viral hepatitis C patients
by: Amira Isaac, et al.
Published: (2021-08-01)

Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients
by: Tarek A Elshazly, et al.
Published: (2019-01-01)

Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis
by: Joo Hyun Oh, et al.
Published: (2022-11-01)

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C
by: Stephanie Popping, et al.
Published: (2018-07-01)

Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil
by: Vinicius Lins Ferreira, et al.

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence
by: Nevine Ibrahim Musa, et al.
Published: (2020-07-01)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
by: Elfi Egmond, et al.

Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan
by: Chen-Hua Liu, et al.
Published: (2020-12-01)

Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
by: Pil Soo Sung, et al.
Published: (2021-01-01)

The impact of direct-acting antivirals on quality of life in patients with hepatitis C virus infection: a meta-analysis
by: Na He, et al.
Published: (2022-07-01)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017-10-01)

Recurrent hepatitis C treatment with direct acting antivirals – a real life study at a Brazilian liver transplant center
by: L.P. Zanaga, et al.

Evaluation of Direct-Acting Antiviral Therapy Efficacy and Post-Treatment Fibrosis with Noninvasive Markers in Patients with Chronic Hepatitis C
by: Fatma Seda KEÇELİ, et al.
Published: (2023-12-01)

Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism
by: Jucéli Márcia Hendges Sparvoli, et al.
Published: (2023-01-01)

Angiopoietin-2 as a predictor of fibrosis regression in chronic hepatitis C virus patients after direct-acting antiviral drugs
by: Amira Isaac, et al.
Published: (2021-12-01)

HCV-Specific T Cell Responses During and After Chronic HCV Infection
by: Hendrik Luxenburger, et al.
Published: (2018-11-01)

Prognosis of late elderly patients with chronic hepatitis C after achieving a sustained viral response by direct‐acting antivirals
by: Satoshi Takakusagi, et al.
Published: (2021-01-01)

An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease
by: Fabrizio Fabrizi, et al.
Published: (2021-10-01)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
by: Andrew Hill, et al.
Published: (2018-04-01)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
by: Cassia Leal, et al.
Published: (2023-01-01)

Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals
by: Pil Soo Sung, et al.
Published: (2020-04-01)

Direct-acting antivirals: a new strategy in the treatment of hepatitis C virus infection in patients with cirrhosis
by: Mariana Avricenco
Published: (2019-12-01)